Devonian Health Group Inc. announced the nomination of Mr. Jacques Bernier, BPharm., MBA and Dr. Louis Flamand, PhD. effective as of May 30, 2017. From 2008 until 2014, Mr. Bernier was CEO of Folia Biotech Inc., a clinical stage biopharmaceutical corporation focused on exploiting its proprietary immune-therapeutic platform to bring to market therapeutic products in oncology and certain infectious diseases.

During his tenure, he has concluded several business partnerships that have strengthened the development of Folia's technology. Prior to joining Folia, Mr. Bernier acquired a broad management experience as the owner of a group of pharmacies and as a member of the Board of Directors of various pharmaceutical corporations. He has a profound understanding of the pharmaceutical industry and an acute experience in business development.

Dr. Flamand is a full professor and vice-chair of the department of microbiology-infectious-disease-immunology at the Faculty of medicine, University Laval and senior researcher in the division of infectious and immune diseases at the CHU de Quebec research center. he is President of the biohazards risk committee at University Laval. He is also member of the HHV-6 Foundation scientific advisory board since 2006.

The corporation also announced that as of May 30, 2017, Mr. Francois Michaud will not be acting as Chief Financial Officer of the corporation. Ms. Colette Laurin, the corporate's Corporate Controller, will assume Mr. Michaud's responsibilities as the corporation's interim Chief Financial Officer. The corporation also announced Mr. Matt Peppler has resigned as a member of the Corporation's Board of Directors.